TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06028685

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupoint stimulation
Description: The experimental group will receive low-level laser stimulation on seven acupoints, including Shenmen (HT7), Neiguan (PC6), Hegu (LI4), Zusanli (ST36), Yanglingquan (GB34), Sanyinjiao (SP6), and Taixi (KI3). The stimulation will be administered three times per week for a duration of six weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acupoint stimulation(placebo)
Description: The control group will receive sham low-level laser stimulation on seven acupoints, including Shenmen (HT7), Neiguan (PC6), Hegu (LI4), Zusanli (ST36), Yanglingquan (GB34), Sanyinjiao (SP6), and Taixi (KI3), without emitting laser beams.The stimulation will be administered three times per week for a duration of six weeks.
Study: NCT06089356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate
Description: valproate once daily
Study: NCT04550988

Intervention type: OTHER
Intervention: feasibility study
Description: The aim of this study is to evaluate the possibility of establishing a patient-based ultrasound monitoring of the knee (representing a target joint accessible with any hand) with a handheld device.
Study: NCT05059535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard pain relievers
Description: Knee arthroscopy will be performed ansd patients will receive standard pain relievers in confomtity with the current practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard pain relievers
Description: Knee arthroscopy will be performed ansd patients will receive standard pain relievers in confomtity with the current practice
Study: NCT04570436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin 600 mg
Description: participants will receive an oral dose of gabapentin 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin 1200 mg
Description: participants will receive an oral dose of gabapentin 1200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin 1800 mg
Description: participants will receive an oral dose of gabapentin 1800 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diazepam 20 mg
Description: participants will receive an oral dose of 20 mg dose of diazepam

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: participants will receive an oral dose of placebo
Study: NCT06429566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB001 recombinant peptide spray low dose group、high dose group
Description: Administrated oral spray. Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, no more than 29 times，The dosage of the group is 0.108mg/spray for low dose group and 0.216mg/spray for high dose group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB001 recombinant peptide spray low dose group、high dose group
Description: Administrated oral spray. Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, no more than 29 times，The dosage of the group is 0.108mg/spray for low dose group and 0.216mg/spray for high dose group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB001 recombinant peptide spray placebo
Description: Administrated oral spray.Each subject will take oral GB001 recombinant peptide spray placebo 4 times a day, 4 sprays each time, no more than 29 times
Study: NCT06497452

Intervention type: DRUG
Intervention: Glofitamab
Description: Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling
Study: NCT06126354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin human
Description: Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin human
Description: Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide Acetate
Description: Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
Study: NCT05313828

Intervention type: DRUG
Intervention: Acyclovir
Description: acyclovir 4 times /day

Intervention type: DRUG
Intervention: Acyclovir
Description: acyclovir 4 times /day

Intervention type: DRUG
Intervention: Acyclovir
Description: acyclovir 4 times /day

Intervention type: DRUG
Intervention: Acyclovir
Description: acyclovir 4 times /day

Intervention type: DRUG
Intervention: Tobramycin
Description: tobramycin 4 times /day

Intervention type: DRUG
Intervention: Tobramycin
Description: tobramycin 4 times /day

Intervention type: DRUG
Intervention: Tobramycin
Description: tobramycin 4 times /day

Intervention type: DRUG
Intervention: Tobramycin
Description: tobramycin 4 times /day

Intervention type: DRUG
Intervention: Fluorometholone
Description: Fluorometholone 4 times/ day

Intervention type: DRUG
Intervention: Fluorometholone
Description: Fluorometholone 4 times/ day

Intervention type: DRUG
Intervention: Sodium Hyaluronate
Description: Sodium Hyaluronate 4 times/day
Study: NCT06126354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate
Description: Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Growth Hormone
Description: Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Growth Hormone
Description: Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral
Description: Synthetic pure glucocorticoid used to induce temporary insulin resistance, administered orally as seven 1-mg doses over 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Synthetic pure glucocorticoid used to induce temporary insulin resistance, administered orally as seven 1-mg doses over 72 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: [6,6-2H2] D-glucose
Description: Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.~(Non-investigational)
Study: NCT05618938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocabado's approach
Description: Group A will be treated with Rocabado's approach. Rocabado' approach will be comprised of six exercises.~1. Rest position of the tongue~2. Control of TMJ rotation~3. Rhythmic stabilization technique~4. Axial extension of the neck The patients will receive Rocabado's approach consisting 6 repetitions six times a day thrice per week for four weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kraus exercises
Description: Group B will be treated with Kraus exercises. Kraus exercises will be comprised of eight exercise programs.~1. Tongue position at rest~2. Teeth apart: the patient will be educated to maintain the teeth apart can be therapeutic, which facilitates the resting tongue position~3. Nasal-diaphragmatic breathing~4. Tongue up and wiggle~5. Strengthening~6. Touch and bite: Proprioceptive re-education: Lateral deviation The patients will receive Kraus exercises with the frequency of 2 sets and 10 repetitions twice a day three times per week for four weeks
Study: NCT06126354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [6,6-2H2] D-glucose
Description: Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.~(Non-investigational)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% D-glucose (aq)
Description: 20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.~(Non-investigational)
Study: NCT04954456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS31901
Description: QLS31901 is a bispecific antibody specifically targeting PD-L1 and TGF-β.In part 1,the QLS31901 will be administered in sequential cohorts on day 1 of every 21-day cycle (3 weeks) via IV infusion.In part 2,the QLS31901 will be administered in parallel cohorts(selected dose and dosing frequency ) on day 1 of every 2week or every 3week via IV infusion
Study: NCT06126354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% D-glucose (aq)
Description: 20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.~(Non-investigational)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BOOST Plus
Description: Nutritional supplement will be administered to provide three standardized mixed meals on the day before the pancreatic clamp.~(Non-investigational)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BOOST Plus
Description: Nutritional supplement will be administered to provide three standardized mixed meals on the day before the pancreatic clamp.~(Non-investigational)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Harvard Apparatus PHD ULTRA CP syringe pump
Description: Device: Harvard Apparatus PHD ULTRA CP syringe pump Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.~(Non-investigational)
Study: NCT06057298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC)
Description: Patient-tailored HIPEC is performed by the closed-abdomen technique with the following drugs selected according to the results of the sensitivity tests on the organoid-based preclinical model:~* Oxaliplatin 360 mg/mq for 30 min.~* Oxaliplatin 200 mg/mq for 120 min.~* Mitomycin-C 35mg/mq for 60 min.~* Mitomycin-C 3.3 mg/mq/l of perfusate + cisplatin 25 mg/mq/l of perfusate for 60 min. (perfusate volume l. 4-6)
Study: NCT06126354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harvard Apparatus PHD ULTRA CP syringe pump
Description: Device: Harvard Apparatus PHD ULTRA CP syringe pump Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.~(Non-investigational)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Description: Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.~(Non-investigational)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Description: Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.~(Non-investigational)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline (0.9% NaCl, aq), variable rate (as needed)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal saline (0.9% NaCl, aq), variable rate (as needed)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human albumin
Description: Human albumin (5%, aq), 0.4 g per 100 mL of infusion (0.4% (w/v) in insulin and OCT/GCG/GH bags)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human albumin
Description: Human albumin (5%, aq), 0.4 g per 100 mL of infusion (0.4% (w/v) in insulin and OCT/GCG/GH bags)
Study: NCT05205330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR6086
Description: oral CR6086, twice a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR6086
Description: oral CR6086, twice a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR6086
Description: oral CR6086, twice a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR6086
Description: oral CR6086, twice a day for 14 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGEN2034
Description: AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGEN2034
Description: AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGEN2034
Description: AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGEN2034
Description: AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle
Study: NCT06165783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercises and Ultrasound
Description: describe the rationale and methodology for evaluating the effect of using therapeutic exercises and ultrasound in the rehabilitation of partially injured hamstring muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercises and Ultrasound
Description: describe the rationale and methodology for evaluating the effect of using therapeutic exercises and ultrasound in the rehabilitation of partially injured hamstring muscles
Study: NCT04049630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEV 1 mg/kg
Description: A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEV 1,5 mg/kg
Description: A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEV 2,5 mg/kg
Description: A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5 tablets of placebo will be administrated to the participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5 tablets of placebo will be administrated to the participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5 tablets of placebo will be administrated to the participants.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 tablets of placebo will be administrated to the participants.
Study: NCT04332796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chorhexidine scrub
Description: Chorhexidine scrub was given to patients for 4 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZnO-NPs socks
Description: ZnO-NPs socks was given to patients for 4 weeks

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination of chorhexidine scrub and ZnO-NPs socks
Description: Combination of chorhexidine scrub and ZnO-NPs socks was given to patients for 4 weeks
Study: NCT05426434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine (DP)
Description: DP (D-Artepp) will be supplied by Fosun Pharma, China. DP will consist of three 40mg/320mg) tablets given once a day for three consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine pyrimethamine (SP)
Description: SP (G-COSPE) will be supplied by Fosun Pharma, China. SP will be given as a single dose consisting of three 500mg/25mg tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine pyrimethamine (SP)
Description: SP (G-COSPE) will be supplied by Fosun Pharma, China. SP will be given as a single dose consisting of three 500mg/25mg tablets.
Study: NCT06121063

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: CCT-102 A and CCT-102 B
Description: 2 day oral regimen
Study: NCT06382012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg
Description: Fosaprepitant 150mg IV administered over 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4 mg
Description: Ondansetron 4mg IV administered over 15 minutes
Study: NCT06074705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1471a
Description: Intravenous administration on Day 1 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1471a
Description: Intravenous administration on Day 1 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1471a
Description: Intravenous administration on Day 1 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1471a
Description: Intravenous administration on Day 1 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1471a
Description: Intravenous administration on Day 1 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1471a
Description: Intravenous administration on Day 1 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1471a
Description: Intravenous administration on Day 1 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1471a
Description: Intravenous administration on Day 1 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1471a
Description: Intravenous administration on Day 1 of each 28-day cycle
Study: NCT04685902

Intervention type: DEVICE
Intervention: One-way speaking valve
Description: One-way speaking valve is a small device that attaches to the tracheostomy tube, to allows tracheostomy patient to breathe in through his or her trach tube. After the inhalation, the speaking valve closes. Air is breathed out (exhaled) up through the vocal cords, then through the mouth and nose.
Study: NCT05280301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sous Vide Device (SVD)
Description: A basin will be filled to the marked line with water from jugs at room temperature, for each frozen extremity. The sous vide device (SVD) will be attached to the distal edge of the basin. The SVD will be turned on and set to maintain the bath at a constant 38 degrees celsius for 30 minutes duration. The thermometers will be powered on continuously and the researcher will record temperatures simultaneously from each thermometer and the SVD every 2 minutes. At the end of the 30 minute treatment, the extremity assessed by the researcher for warmth and pliability. If the extremity still feels cold or frozen, an additional 30 minutes in the water bath will commence, with subsequent reassessment. Rewarming will be considered complete when the affected tissue becomes red or purple, soft, and pliable.
Study: NCT06643117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FYB206
Description: FYB206 (Keytruda biosimilar candidate - test product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle combined with chemotherapy in the first year (treatment Cycles 1 to 17)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FYB206
Description: Open-label treatment with FYB206 combined with chemotherapy (Cycles 18-34) to assure treatment continuation for trial patients up to a total of 2 years (a total of 34 treatment cycles)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Keytruda
Description: Keytruda (reference product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle combined with chemotherapy in the first year (treatment Cycles 1 to 17)
Study: NCT06577636

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Propofol anesthesia
Description: EEG-guided infusion of anesthestetics

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Propofol anesthesia
Description: EEG-guided infusion of anesthestetics
Study: NCT05215340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Study: NCT05928013

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurothesiometer
Description: The 'gold standard' device for Vibration Perception Threshold testing

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NERVE
Description: The experimental device for Vibration Perception Threshold testing developed by the project team
Study: NCT06416436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a fixed dose of 1680 mg IV route every 4 weeks (1680 mg on Day 1 of each 28-day cycle), which is an approved dosage for atezolizumab, as outlined in the prescribing information.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SBRT)
Description: Ultra-High Doses of Ablative Radiosurgery~SBRT is delivered to metastases over 3-5 fractions within 1-2 weeks
Study: NCT05215340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Study: NCT06273098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bladder Health Education
Description: This will be a combination of bladder health education and awareness events, additional resources such as a water station to support healthy bladder behaviors, and tailored changes to classroom bathroom policies that are TBD (e.g. mobile technology bathroom passes).